Malik Ahmed, MD
Psychiatry · Saint Louis, MONPI 1770557985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 24.1% of the total. Reporting peaked in 2023 at $118 and has fallen 83.7% since, to $19 in 2025. That places this record below the midpoint for psychiatry clinicians in MO, where the typical reported total is $226.
Across 11 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$53
- Lundbeck LLC$41
- Abbott$35
- Merck$20
- Axsome Therapeutics, Inc.$19
- Takeda Pharmaceuticals U.S.A., Inc.$19
- plus $34 from 2 others
Across 11 payments — averaging $6323.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$70K
What the payments were for
- Food & beverage$222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Lundbeck LLC | 2 | $41 |
| Abbott | 1 | $35 |
| Merck | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $17 |
How this compares
$222 in reported general payments places this provider in the 45th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 16 | $43,445 |
| Paliperidone ErPaliperidone | 14 | $7,045 |
| Aripiprazole | 45 | $2,234 |
| Divalproex Sodium ErDivalproex Sodium | 37 | $1,536 |
| Olanzapine | 44 | $874 |
| Quetiapine Fumarate | 54 | $637 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 20 | $616 |
| Trazodone Hcl | 112 | $608 |
| Hydroxyzine Hcl | 39 | $389 |
| Bupropion XlBupropion Hcl | 31 | $330 |
| Divalproex Sodium | 16 | $302 |
| Venlafaxine Hcl | 13 | $261 |
| Buspirone Hcl | 13 | $252 |
| Duloxetine Hcl | 23 | $242 |
| Mirtazapine | 22 | $223 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.